This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2021. The Annual Report is attached below and also available on www.acaciapharma.com in the Investors/Financial Reports and Presentations section. Contacts Acacia Pharma Group plcMike Bolinder, CEO+44 1223 919760 / +1 317 505 1280IR@acaciapharma.com International MediaFrazer Hall, Mark Swallow, David DibleMEDiSTRAVA Consulting+44 20 3928 6900acaciapharma@medistrava.com US InvestorsLifeSci AdvisorsIrina Koffler+1 917-734-7387ikoffler@lifesciadvisors.comMedia in Belgium and the NetherlandsChris Van Raemdonck+32 499 58 55 31chrisvanraemdonck@telenet.be
Attachment
Acacia Pharma Annual Report 2021